Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2025-01-17 pm EST			5-day change	1st Jan Change
17.36 ^USD	-0.46%		-2.25%	-3.88%

Jan. 13	Bausch + Lomb Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 11:15 AM
Jan. 13	Bausch + Lomb Acquires Whitecap Biosciences, Financial Details Not Disclosed	MT

Bausch + Lomb Corporation acquired ELIOS Vision, Inc.

December 10, 2024

Bausch + Lomb Corporation (NYSE:BLCO) acquired ELIOS Vision, Inc. on December 11, 2024. Leerink Partners LLC acted as financial advisor for ELIOS Vision, Inc. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor for ELIOS Vision, Inc. Outcome Capital, LLC served as financial advisor to
Bausch + Lomb Corporation (NYSE:BLCO) completed the acquisition of ELIOS Vision, Inc. on December 11, 2024.

Latest news about Bausch + Lomb Corporation

Bausch + Lomb Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 11:15 AM	Jan. 13
Bausch + Lomb Acquires Whitecap Biosciences, Financial Details Not Disclosed	Jan. 13	MT
Bausch + Lomb Brief: Says "Bolsters Pipeline" with Acquisition of Whitecap Biosciences	Jan. 13	MT
Bausch + Lomb Brief: Launching Lenses in the European Union	Jan. 13	MT
Bausch + Lomb Corporation Launches enVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in European Union	Jan. 13	CI
Bausch + Lomb Corporation acquired Whitecap Biosciences LLC.	Jan. 12	CI
City Therapeutics, Inc. Announces Strategic Collaboration with Bausch + Lomb to Develop Novel RNAi-Based Treatment for Geographic Atrophy	Jan. 10	CI
City Therapeutics, Inc. announced that it has received funding from Bausch + Lomb Corporation	Jan. 09	CI
Bausch Health Says Bausch + Lomb Subsidiary Sale Under Consideration	Dec. 12	MT
Bausch + Lomb Brief: Does not intend to provide additional detail until further disclosure is "Appropriate or Necessary"	Dec. 12	MT
Bausch + Lomb Brief: Adds "That process is ongoing, and there can be no assurance that it will result in a transaction"	Dec. 12	MT
Bausch + Lomb Brief: Says a potential sale is one of several options being explored to complete a full separation from Bausch Health	Dec. 12	MT
Bausch + Lomb Brief: Comes After Financial Times reported that Blackstone may drop out of consortium bidding on It	Dec. 12	MT
Bausch + Lomb Brief: Responding to Rumors of a Potential Sale	Dec. 12	MT
Bausch + Lomb Responds to Rumors of a Potential Sale	Dec. 12	CI
TSX Closer: The Market Surges as the Bank of Canada Makes Its Jumbo Cut, Further Cuts Predicted	Dec. 11	MT
Sector Update: Financial Stocks Advance Late Afternoon	Dec. 11	MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	Dec. 11	MT
Sector Update: Financial Stocks Rise Wednesday Afternoon	Dec. 11	MT
Sector Update: Financial	Dec. 11	MT
TSX up 105 Points at Midday, With Info Tech, Energy, Higher; Healthcare The Biggest Decliner	Dec. 11	MT
Bausch + Lomb Shares Fall After Citigroup Downgrade, Blackstone's Reported Exit From Takeover Bid	Dec. 11	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	Dec. 11	MT
Citigroup Downgrades Bausch + Lomb to Neutral From Buy	Dec. 11	MT
Bausch + Lomb Buys Elios Vision	Dec. 11	MT

Chart Bausch + Lomb Corporation

Duration

Period

BLCO: Dynamic Chart

Company Profile

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Employees

13,300

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

More about the company